Hutchison China MediTech Limited ("Chi-Med") is a China-based globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.

Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is listed on the London Stock Exchange’s AIM market (AIM: HCM). It is majority owned by CK Hutchison Holdings Limited (SEHK: 0001), a leading international conglomerate committed to innovation and technology with over a quarter of a million employees in more than 50 countries and annual sales of over US$50 billion.

http://www.chi-med.com/eng/global/home.php

Global Phase III HPML-004 maintenance study starts

RNS


RNS Number : 4497J

Hutchison China Meditech Limited

17 July 2013












Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)





Nutrition Science Partners announces initiation of NATRUL-4,
the maintenance study of the global Phase III trial for HMPL-004





London: Wednesday, 17 July 2013: Nutrition Science Partners, a 50/50 joint venture between Chi-Med and Nestlé Health Science, today announces that the first patient has begun treatment in the second global Phase III study of HMPL-004, NATRUL-4, for mild-to-moderate ulcerative colitis ("UC").



HMPL-004 is a proprietary, novel, botanical oral drug in late stage development for the treatment of inflammatory bowel disease ("IBD"). It has undergone multiple clinical trials in North America, Europe and Asia, which showed efficacy in the induction of clinical response, remission, and mucosal healing; as well as a clean safety profile.



NATRUL-4 is a global Phase III study designed to evaluate the efficacy and safety of HMPL-004 as maintenance therapy in adults with mild-to-moderate active UC. It consists of an open-label induction treatment phase and a randomised, double-blind, placebo controlled maintenance therapy phase. Patients entering the maintenance phase of this study are those who have achieved clinical remission or response during their participation in either a randomised double-blind, placebo controlled HMPL-004 induction study (NATRUL-3 or NATRUL-5), or the 8-week open-label HMPL-004 induction treatment phase of the study. Eligible patients (clinical remitters and responders) will be randomised to receive either HMPL-004 at 1,800 mg/day or placebo for 52 weeks as maintenance therapy.



The primary endpoint of this study is the proportion of patients who are in remission after 52 weeks of maintenance treatment, following either successful induction therapy to achieve remission, or successful induction therapy to achieve response.



Key secondary endpoints of this study include the proportion of patients that have maintained remission only after induction into remission; the proportion of patients that are in response after induction into either remission or response; and the proportion of patients that have maintained response following induction into response.





Ends

Interim Results

RNS


RNS Number : 4081K

Hutchison China Meditech Limited

30 July 2013










Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Interim Results for the Six Months Ended 30 June 2013



Continued strong growth, especially in Drug R&D and China Healthcare. Outlook positive.





London: Tuesday, 30 July 2013: Chi-Med, the China-based healthcare and consumer products group, today announces its unaudited financial results for the six months ended 30 June 2013.



Group results are reported for the first time under the new International Financial Reporting Standard, IFRS 11 "Joint Arrangements" ("IFRS11"), which establishes the equity accounting principle for the reporting of joint ventures ("JVs") and means that the income statements and statements of financial position of JVs will no longer be proportionately consolidated. However, total revenues of the JVs will continue to be disclosed under the divisional summaries below.



Results are reported in US dollar currency unless otherwise stated.





Group Results

· Revenue, under IFRS11, on continuing operations up 74% to $17.6 million (H1 2012: $10.1m).

· Net profit attributable to Chi-Med equity holdersgrew 598% to$3.3 million (H1 2012: -$0.7m).

· Solid cash position: cash and cash equivalents at the Chi-Med Group level of $43.8 million (31 December 2012: $30.8m) in addition, and not included at the Group level, cash and cash equivalents held at the JV level totalled $101.4 million (31 December 2012: $62.4m).



China Healthcare Division

· Sales of subsidiaries and JVs up 22% to $227.5 million (H1 2012: $187.0m).

· Net profit attributable to Chi-Med equity holders up 18% to $14.4 million (H1 2012: $12.3m).

· Continued substantial growth in prescription drug and distribution businesses; over-the-counter ("OTC") drug business surge due to H7N9 outbreak in China, raw material prices however remain high.

· Value of land holdings expected to more than cover the cost of planned relocation and expansion of production facilities.

· Cash and cash equivalents held in our China Healthcare Division JVs totalled $75.2 million (31 December 2012: $62.4m).



Drug R&D Division

· Revenue up 265% to $10.5 million (H1 2012: $2.9m) due to a development milestone from AstraZeneca Plc ("AstraZeneca") and service income from Nutrition Science Partners Limited ("NSP") and Janssen Pharmaceuticals Inc. part of the Johnson & Johnson group of companies ("J&J").

· Net loss attributable to Chi-Med equity holders up 8% to $4.8 million (H1 2012: -$4.5m) due to start of NSP investment in HMPL-004 Phase III trials.

· Aggregate cash and equityinjections and contractual obligations from partners into Drug R&D Division subsidiaries and JVs during the period totalled $38.1 million (H1 2012: $0.6 m).

· Seven clinical trials accelerating rapidly and building value. Six Phase I/Ib oncology trials in China and Australia as well as NSP's Phase III inflammatory bowel disease ("IBD") trial on HMPL-004 in the United States. Spending during the period by Hutchison MediPharma Limited ("HMP") and its partners on these seven clinical programmes totalled $15.2 million (H1 2012: $6.9m).

· Cash and cash equivalents held in our Drug R&D Division JVs totalled $26.2 million (31 December 2012: nil).





Consumer Products Division

· Sales on continuing operations up 32% to $5.5 million (H1 2012: $4.2m).

· Net loss on continuing operations attributable to Chi-Med equity holders of $0.4 million (H1 2012: -$0.5m).

· Discontinuation of operations of Sen France and infant formula in China with total net loss attributable to Chi-Med equity holders of $1.4 million, of which $0.4 million is non-cash.

· Continuing expansion of the broad organic and natural product line of Hutchison Hain Organic Holdings Limited ("Hutchison Hain Organic").



Christian Hogg, CEO of Chi-Med, said:



"The new IFRS11 accounting standard means we can no longer consolidate the revenues of our JVs, and we therefore report a considerable reduction in Group consolidated revenues. However, the Divisional results show continued strong revenue growth, as does our Consolidated Group profit.



There has been much comment on whether economic growth in China is slowing, but it is quite clear this is not the case in the pharmaceutical sector, where the progressive widening and deepening of the State's National Healthcare Plan and the growth in personal incomes continue to drive strong growth. This is reflected in the results for our China Healthcare Division, which will also benefit in future from planned pricing and the easing of currently high raw material costs on one of our lead products. We also expect to benefit from the values of our JVs' land holdings which we expect to more than cover the costs of the planned relocation and expansion of the production facilities.



Our Drug R&D Division continues to make very impressive strides in its drug development programme and in partnership agreements with leading multinational pharmaceutical companies, all of which are adding substantial shareholder value and are set for continued major growth. Aggregate cash and equity injections and contractual obligations to HMP from these partnerships were $38.1 million compared to $0.6 million in the same period last year. Our partnerships are funding the seven clinical trials we now have under way, including Phase III trials of our lead drug candidate HMPL-004 in the US and the six Phase I trials of our other drug candidates, which are showing exciting promise. We look for further continued strong progress and for potential additional steps in partnership agreements.



Our Consumer Products Division is now focused on expanding its profitable growth categories with Hutchison Hain Organic by launching new products into the Hong Kong and mainland China market, as well as into selected other countries in Asia.



Overall, this has been another period of good progress, which further demonstrates the strength of our growth platform and its continued long-term potential. We expect profitable growth to continue for the second half of 2013 and beyond with further substantial creation of shareholder value."



Ends

IC VIEW

China's economy may be slowing, but spending on healthcare is not. Trading on a 15 per cent discount to analysts' 600p a share sum-of-the-parts valuations, the shares remain a buy.

A buy in this weeks IC- China's economy may be slowing, but spending on healthcare is not. Trading on 15% discount to analysts 600p a share sum of the parts valuation .

Back to its highs.

Director Deals - Hutchison China Meditech Ltd (HCM)

BFN

Christopher Nash, Non Executive Director, bought 8,506 shares in the company on the 7th August 2013 at a price of 584.00p. The Director now holds 26,506 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com

Analyst briefing on Chi-Med's R&D business

RNS


RNS Number : 5607P

Hutchison China Meditech Limited

03 October 2013












Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)





Analyst briefing on Chi-Med's pharmaceutical R&D business on 9 October 2013





London: Thursday, 3 October 2013: Chi-Med today announces that it will host a briefing to update investors and analysts on Hutchison MediPharma ("HMP"), its majority owned pharmaceutical R&D division, in London on 9 October 2013.



Over the past several years, HMP has built an impressive pipeline of oral, small molecule cancer drugs and proprietary botanical drugs for inflammatory diseases. The briefing will focus on this pipeline.



HMP's current clinical pipeline includes: Fruquintinib, Sulfatinib, Epitinib, Theliatinib and Volitinib, each of which has the potential to treat a number of cancers, and HMPL-004, its lead candidate for ulcerative colitis and Crohn's disease.



In addition, HMP has formed key partnerships with major global pharmaceutical companies, including AstraZeneca and Nestlé Health Science.



The briefing will also cover HMP's pre-clinical research and the ongoing Phase III clinical development of HMPL-004, which is being undertaken by Nutrition Science Partners, a 50:50 joint venture between Chi-Med and Nestlé Health Science.



During the briefing, Dr Andrew Mortlock, Vice President of Cancer Research and Development Projects of AstraZeneca will give a presentation entitled, "Oncology in China".



Other key presenters at the briefing will be:



· Dr Weiguo Su, Ph.D. Chief Scientific Officer of HMP. Prior to joining HMP, Dr Su spent fifteen years with Pfizer's US R&D organisation where he was responsible for the delivery of several high quality new drug candidates into the clinic.



· Dr Hua Mu, Chief Medical Officer of HMP. Prior to joining HMP, Dr Mu worked at Roche, Biogen Idec, Abraxis and most recently, Genentech. During his career, he has been involved in the development of a number of successful oncology drugs including Xeloda ®, Abraxane ® and Avastin ®.



Mr Christian Hogg, Chief Executive Officer of Chi-Med, and Mr Johnny Cheng, Chief Financial Officer of Chi-Med, will also give presentations covering HMP's overall R&D strategy and its funding.



The briefing will take place at The Brewery (The James Watt room), 52 Chiswell Street, London, EC1Y 4SD on 9 October 2013 at 9:30 am, with registration starting from 9:15 am. Please contact Ms Janine Hagan by email at janine.hagan@citigatedr.co.uk for registration.



Ends

Lilly Deal for Fruquintinib

RNS


RNS Number : 0695Q

Hutchison China Meditech Limited

09 October 2013












Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Cancer Therapy Collaboration with Lilly





London: Wednesday, 9 October 2013: Hutchison MediPharma Limited ("HMP"), an R&D company majority owned by Chi-Med, today announces that it has entered into a licensing, co-development, and commercialisation agreement in China with Eli Lilly and Company ("Lilly") for Fruquintinib (HMPL-013), a targeted oncology therapy for the potential treatment of various types of solid tumours. Fruquintinib, a selective inhibitor of the Vascular Endothelial Growth Factor ("VEGF") receptor tyrosine kinases, was discovered by HMP and is currently in Phase II testing in China.



Under the terms of the agreement, the costs of future development of Fruquintinib in China, to be carried out by HMP, will be shared between HMP and Lilly. HMP will potentially receive a series of payments of up to US$86.5 million, including upfront payments and development and regulatory approval milestones. Should Fruquintinib be successfully commercialised in China, HMP would receive tiered royalties starting in the mid-teens percentage of net sales. Additional terms of the agreement were not disclosed.



Christian Hogg, Chief Executive Officer of Chi-Med said: "Our belief is that Fruquintinib has potential activity against multiple tumour types with high incidence rates and may benefit patients with significant unmet medical needs in China. The collaboration with Lilly will allow for Fruquintinib to be developed across various tumour types in China and at a far greater speed than if we went alone."



"We are excited to collaborate with Hutchison MediPharma in the development of this potential new cancer therapy," said Jacques Tapiero, Lilly Senior Vice President and President of Emerging Markets. "In Lilly's emerging markets business, we are focused on providing patients with innovative medicines from our own pipeline and through collaborations with respected science-based companies such as HMP. Together, we are committed to help meet the medical needs of oncology patients in China."



Ends

Payment From Janssen Pharmaceuticals

RNS


RNS Number : 0697Q

Hutchison China Meditech Limited

09 October 2013


Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)


Candidate Nomination of Novel Small-Molecule Therapy in Inflammation Triggers Milestone Payment From Janssen Pharmaceuticals, Inc.



London: Wednesday, 9 October 2013: Chi-Med today announces that Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, is set to receive a milestone payment of US$6 million from Janssen Pharmaceuticals, Inc. ("Janssen"), pursuant to the global strategic alliance (the "Agreement") to develop novel small-molecule therapeutics against a target in the area of inflammation/immunology entered into by the companies in June 2010.

The US$6 million milestone was triggered by a compound, the Candidate, discovered by HMP in collaboration with Janssen meeting certain development candidate criteria pursuant to the Agreement. Upon achievement of specific clinical development and approval milestones, HMP may potentially receive up to an additional US$90.5 million and is entitled to royalties on worldwide sales upon commercialisation of a product by Janssen.



Ends

Director/PDMR Shareholding

RNS


RNS Number : 6600Q

Hutchison China Meditech Limited

16 October 2013












Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Director's Shareholding





London: Wednesday, 16 October 2013: Chi-Med received notification on 16 October 2013 that Ms Edith Shih, Non-executive Director and Company Secretary of Chi-Med, purchased 20,000 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP6.20 each on 15 October 2013.



Following this purchase, Ms Shih is beneficially interested in 20,000 Shares, representing approximately 0.04% of the current issued share capital of Chi-Med.





Ends

IC this week - Shares in the Chinese drug developer, which is part of the giant Hong Kong based conglomerate Huchison Whampoa, have gained 25% over the past 12 months after an important deal with Swiss company Nestle to co-develop plant derived medicine HPML- 004 for gastric treatment. The drug is currently undergoing extensive phase lll clinical trials that will report sometime in mid 2014. The biotech research division also has at least five oncology products in its pipeline that are currently at the phase I stage of development. In addition, there is also an extensive Chinese medicine business which analysts value at around £247m . The company also earned a £3m milestone from Janssen Pharmaceuticals as part of an agreement to develop novel inflammation/immunology medicines.


But the major news flow in 2014 will be in connection with the Nestle joint venture and analysts will wait for this before revising their forecasts.

In Shares - Mark Slater manager of MFM Slater growth. Less well understood , are the rich property assets on the balance sheet and the progress being made by Chi-Med's majority owned research and development company , a biotechnology arm he describes as being 'years ahead of the next best Chinese R&D business'.
' I think the shares could double from here quite easily', says Slater.

IC this week continue to rate the shares a buy. Game changer, aim company with 10 bagger innovations.

In IGI this week - Mark Slater Boasting a 'huge pipeline of products' 'I think the shares could double from here quite easily'.

Sinopharm distribution joint venture in China

RNS


RNS Number : 8467V

Hutchison China Meditech Limited

18 December 2013












Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Chi-Med and Sinopharm form China drug distribution and marketing joint venture





London: Wednesday, 18 December 2013: Chi-Med, the pharmaceutical and healthcare company based primarily in China, today announces the establishment of a new joint venture with Sinopharm Group Co. Ltd. ("Sinopharm"). Sinopharm is the largest distributor of pharmaceutical and healthcare products and a leading value added supply chain service provider in China. The joint venture will provide distribution and marketing services to both related and third party pharmaceutical companies in China.



Chi-Med will, through a wholly-owned subsidiary, invest approximately US$9.8 million in cash into Sinopharm Holding HuYong Pharmaceutical (Shanghai) Co., Ltd. ("Huyong") for the subscription of 51% of the equity in the enlarged share capital of Huyong, which will mean that Huyong will be consolidated as a Chi-Med subsidiary. The Chi-Med investment will be largely deployed for expanding future commercial activities, particularly in the area of third party drug sales and marketing. Sinopharm will hold the balance of 49% of the equity in Huyong.



Huyong is a Good Supply Practice ("GSP") certified pharmaceutical and healthcare distribution and marketing company that was originally established in 1993 and subsequently acquired by Sinopharm in 2010. Huyong will be renamed as Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Limited ("Hutchison Sinopharm"). Huyong's profit before tax for the year ended 31 December 2012 was US$1.0 million, and had gross assets at 31 December 2012 of US$29.9 million.



Hutchison Sinopharm will be reported under the China Healthcare Division of Chi-Med which currently comprises three companies: Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited ("HBYS"); Shanghai Hutchison Pharmaceuticals Limited ("SHPL"); and Hutchison Healthcare Limited ("HHL"). The 2012 sales of the China Healthcare Division subsidiaries and jointly controlled entities of Chi-Med were US$350.5 million and net profit attributable to Chi-Med equity holders was US$15.5 million.



Hutchison Sinopharm will provide a platform for synergy across the China Healthcare Division of Chi-Med by utilising the services of the approximately 2,800-person prescription drug and over-the-counter drug sales teams of SHPL and HBYS. A major aspect of the Hutchison Sinopharm business strategy will be to provide sales, distribution, and marketing services to major domestic and multi-national third party pharmaceutical manufacturers. It will also provide a broadened sales and marketing platform for HHL's products and potentially the future novel drugs registered by Hutchison MediPharma Limited, Chi-Med's Drug R&D Division.



This transaction is subject to regulatory approval in China.



Christian Hogg, Chi-Med CEO said: "This strategic investment widens the scope of our China Healthcare Division dramatically by allowing Chi-Med's commercial organisation to market third party pharmaceutical products. We are honoured to partner with Sinopharm in the area of drug distribution and marketing and expect to build a material business based on the complementary strengths of our two groups over the coming years."

Notice of Results

RNS


RNS Number : 6998X

Hutchison China Meditech Limited

16 January 2014














Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Notice of Announcement of 2013 Final Results





London: Thursday, 16 January 2014: Chi-Med will be announcing its final results for the year ended 31 December 2013 on Tuesday, 18 February 2014. An analyst presentation will be held at 9:00am on the same day at Panmure Gordon, 3rd Floor, One New Change, London, EC4M 9AF.





Ends

Final Results

RNS


RNS Number : 2681A

Hutchison China Meditech Limited

18 February 2014














Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)



Final Results for the year ended 31 December 2013

Continued momentum. Continued very considerable growth potential.



London: Tuesday, 18 February 2014: Chi-Med today announces its final results for the year ended 31 December 2013.



Consolidated Group Results (IFRS11)

· Revenue from continuing operations up 106% to $46.0 million (2012: $22.4m), not including sales at the JV level which totalled $390.6 million (2012: $345.3m).

· Operating profit up 65% to $9.6 million (2012: $5.8m) including non-recurring charge of $2.0 million.

· Net profit attributable to Chi-Med equity holders up 63% to $5.9million (2012: $3.6m).

· Cash and cash equivalents at the Chi-Med Group level of $46.9 million (31 December 2012: $30.8m) in addition, and not included at the Group level, cash and cash equivalents held at the JV level totalled $99.0 million (31 December 2012: $62.4m).



Results are reported in US dollar currency unless otherwise stated.



Christian Hogg, Chi-Med CEO, said: "Chi-Med has had a highly successful 2013. We have propelled our revenues and profit, and the drivers of this success are set to continue.



Our Drug R&D Division has taken a major step forward by signing a new licensing deal with Eli Lilly and cementing its collaboration with Janssen to add to those it already has with AstraZeneca and Nestlé Health Science. Its revenues have increased sharply due to payments from these partners. It has significantly progressed its six clinical stage drug candidates either reaching, or closing in on, proof-of-concept. We have spent over $30 million on clinical trials in 2013, with our partners funding the great majority of these clinical costs. Several of our compounds in clinical development showed impressive results in 2013 - in two cases for treatment of certain tumour types, for which there are few, if any, treatment options approved on the global market.



By the end of 2013, Chi-Med had received $72 million of upfront and milestone payments and equity injections from our four partners. Looking ahead, this cash flow should escalate. In addition to funding the vast majority of clinical costs on our partnered drug candidates, our partners will contribute, subject to clinical success, up to approximately $1.2 billion in development, approval, and commercial milestones and option payments, as well as customary royalties on net sales.



Our China Healthcare Division continues to grow rapidly with net profit attributable to Chi-Med equity holders up 20% in 2013, again demonstrating the major potential in the China pharmaceutical market. Its sales and profitability are now benefitting from the normalisation of raw material prices and, this year, we hope to start crystallising the value in our manufacturing property portfolio. To take advantage of the opportunity for Chi-Med to provide sales, distribution and marketing services to major Chinese and multi-national third party pharmaceutical manufacturers as well as our own Drug R&D Division, we have formed a joint venture with Sinopharm.



Our Consumer Products Division grew sales 23%, driven by the progress of Hutchison Hain Organic, while Sen France and aspects of our China infant formula businesses have been discontinued.



Trading has started well this year. Sales and profit in our China Healthcare Division are well ahead of 2013 levels, as a result of effective execution and continued normalisation of raw material costs. We expect 2014 to be a breakout year for our Drug R&D Division as we publish clinical data on Volitinib, Fruquintinib and Sulfatinib, in each case outlining next stage clinical plans. On HMPL-004 we will reach our Interim Analysis on NATRUL-3, our Phase III induction study, and publish status in mid-2014. We expect also to start Phase I trials on our spleen tyrosine kinase ("Syk") inhibitor for inflammation in Australia, which would elevate the profile of this very high potential programme. Our Consumer Products Division's continuing operations have started well and we expect the refocused operations to be profitable this year.



The opportunities facing us are very considerable and we believe we will deliver further substantial shareholder value this year and beyond."



Highlights

China Healthcare Division - Continuing strong growth

· Sales of subsidiaries and joint ventures ("JVs") up 13% to $394.6 million (2012: $350.5m). Organic expansion of own brands (up 14% to $343.0m) with both prescription and over-the-counter ("OTC") cardiovascular drug sales being the strongest. Third party OTC drug distribution business up only 2% to $51.6 million due to shedding of lower margin activity.

· Net profit attributable to Chi-Med equity holders up 20% to $18.6 million (2012: $15.5m).

· Entered into an agreement to establish a new 51% Chi-Med owned JV, subject to regulatory approval, with Sinopharm Group Co. Ltd. (HKSE:1099) ("Sinopharm") to provide sales, distribution, and marketing services to major Chinese and multi-national third party pharmaceutical manufacturers.



Drug R&D Division - Step-change developments approaching

· Revenue up 327% to $29.5 million (2012: $6.9m) as a result of $22.2 million in upfront and milestone income and $7.3 million in service income from our partners.

· Secured $54.8 million in third party cash injections for Hutchison MediPharma Limited's ("HMP") activities during 2013, bringing the total to $103.6 million since 2010.

· Net lossattributable to Chi-Med equity holders of $2.4 million (2012: net profit $2.8m) due primarily to the consolidation of $8.8 million (2012: nil) non-cash share of the loss of Nutrition Science Partners Limited ("NSP"), the JV with Nestlé Health Science SA ("Nestlé Health Science"). NSP, which is enrolling patients in the HMPL-004 global Phase III registration trial, was entirely self-funded in 2013, and will be until the Interim Analysis in mid-2014, by the initial cash equity investment in NSP by Nestlé Health Science.

· Progressed global development of Volitinib (HMPL-504), a c-Met inhibitor in oncology, in partnership with AstraZeneca AB (publ) ("AstraZeneca") in Phase I in Australia and China. Phase I dose escalation, initiation of which triggered a $5 million milestone in mid-2013, will be completed by early 2014 and results will be published at the American Society of Clinical Oncology ("ASCO") meetings in June 2014. Volitinib has demonstrated very encouraging anti-tumour activity in Phase I in certain tumour-types, some of which have no approved therapies on the global market. Phase II studies in papillary renal cell carcinoma ("PRCC") will start in early 2014 in the United States and global Phase III initiation is scheduled for 2015.

· Completed exclusive license and collaboration agreement for China with Eli Lilly and Company ("Lilly") on Fruquintinib (HMPL-013), our highly selective vascular endothelial growth factor receptor ("VEGFR") inhibitor. Lilly will share development costs and pay HMP up to $86.5 million in upfront payments and development and regulatory milestones and upon commercialisation in China tiered royalties starting in the mid-teens percentage of net sales. Fruquintinib, which received Phase II/III clearance from the China Food & Drug Administration ("CFDA") in mid-2013, will start Phase II studies in several tumour types, and a Phase III registration study on one tumour type, in China in 2014.

· Immunology collaboration with Janssen Pharmaceuticals, Inc. ("Janssen"), the pharmaceutical division of Johnson & Johnson, progressed well in 2013. Janssen nominated a compound, HMPL-507, discovered by HMP, for further development thereby triggering a $6 million milestone payment. Janssen will be responsible for all development costs and will potentially pay HMP up to an additional $90.5 million in development and regulatory approval milestones, and royalties on worldwide sales upon commercialisation.

· Beyond the four partnered drug candidates, HMP has effectively progressed three further high potential small molecule oncology drug candidates with stand-out results on Sulfatinib which in 2013 demonstrated very encouraging anti-tumour activity in certain tumour types, some of which have very limited treatment options approved on the global market.

· In discovery, HMP nominated HMPL-523 in early 2013, a novel Syk inhibitor, for rheumatoid arthritis and intends to start Phase I trials in Australia in early 2014.



Consumer Products Division - Refocused

· Sales on continuing operations up 23% to $12.5 million (2012: $10.2m) driven by progress on the expansion of the range of Hutchison Hain Organic Holdings Limited ("HHO") products in Asia.

· Non-recurring $2.0 million in costs associated with the discontinuation of the Sen France and aspects of the China infant formula businesses.

· Net loss attributable to Chi-Med equity holders on continuing operations of $0.5 million (2012: -$0.9m).



Group results are reported for the full year for the first time under IFRS11 "Joint Arrangements" ("IFRS11"), which establishes the equity accounting principle for the reporting of JVs and means that the income statements and statements of financial position of JVs will no longer be proportionately consolidated. However, total revenues of the JVs will continue to be disclosed throughout the announcement.



A presentation for analysts will be held at 9:00 a.m. today at the offices of Panmure Gordon at 3rd Floor, One New Change, London EC4M 9AF.

The Annual General Meeting of Chi-Med will be held at 4th Floor, Hutchison House, 5 Hester Road, Battersea, London SW11 4AN on Thursday, 8 May 2014 at 10:00 a.m.



Ends

Hutchison China MediTech Ltd (HCM:LSE) set a new 52-week high during today's trading session when it reached 735.00. Over this period, the share price is up 67.05%.

A buy in last weeks IC